I am a translational lymphoma researcher and associate professor at the NYU Perlmutter Cancer Center (PCC). My research focuses on the relationship between lymphoma, microenvironment, and systemic immunity. I lead an R01 funded study of the microbiome in DLBCL, and and serve as PI on a multi-investigator R01 investigating new immune strategies for CAR T cells. I have presented data on immune profiling in Hodgkin lymphoma (HL) at national and international meetings. Clinically, I have led the effort to integrate immune based approaches into lymphoma therapy, through development of the intergroup Phase 2 protocol E4412 combining brentuximab, nivolumab, and ipilimumab in relapsed HL. I have obtained funding for my research from: the NCI, the ACS, the Lymphoma Research Foundation, Doris Duke (internally awarded), and the NCI Clinical Investigator Team Leader Award for my work with ECOG-ACRIN. My expertise in lymphoma immunology makes me well qualified to lead this current project.